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SUMMARY  
Pelizaeus-Merzbacher disease (PMD) is a X-linked leukodystrophy caused by mutations 
in Proteolipid Protein 1 (PLP1), encoding a major myelin protein, resulting in profound 
developmental delay and early lethality. Previous work showed involvement of unfolded 
protein response (UPR) and endoplasmic reticulum (ER) stress pathways, but poor PLP1 
genotype-phenotype associations in patients suggest additional pathogenetic 
mechanisms. Using induced pluripotent stem cell (iPSC) reprogramming and gene-
correction, we here show that PMD patient-derived oligodendrocytes can develop to the 
pre-myelinating stage, but subsequently undergo cell death. Activation of UPR and ER 
stress pathways occurred variably among patient-specific lines carrying different PLP1 
mutations. Instead, mutant oligodendrocytes demonstrated key hallmarks of ferroptosis 
including lipid peroxidation, abnormal iron metabolism and hypersensitivity to free iron. 
Iron chelation rescued mutant oligodendrocyte apoptosis, survival and differentiation in 
vitro, and post-transplantation in vivo. Moreover, systemic treatment of Plp1-mutant 
Jimpy mice with deferiprone, a small molecule iron chelator, reduced oligodendrocyte 
apoptosis and enabled myelin formation. Thus, oligodendrocyte iron-induced cell death 
and myelination is rescued by iron chelation in PMD pre-clinical models.  
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INTRODUCTION 
 Pelizaeus-Merzbacher disease (PMD) is a congenital X-linked recessive leukodystrophy 
caused by mutations in the Proteolipid Protein 1 (PLP1) gene with an incidence of 1:200,000 to 
1:500,000 (Hobson and J., 1999). PLP1 is one of the main protein components in myelin of the 
central nervous system (CNS) and lack of myelination is the main pathological characteristic of 
the disease. Accordingly, the clinical presentation can show pervasive neuro-developmental 
delay and generalized low muscle tone. Early-severe (aka connatal) PMD patients show 
respiratory difficulties and nystagmus at birth and later neurodegeneration and death at early 
teenage years (Woodward, 2008).  
PLP1 mutations comprising gene duplications, and missense point mutations of PLP1 
can result in marked hypomyelination of the CNS (Woodward, 2008). While loss-of-function 
mutations also can occur, these typically show the mildest phenotypes (Sistermans et al., 1996). 
How these PLP1 mutations lead to lack of myelination, however, is not well understood and 
therefore no curative treatment options are currently available. Studies in mice and tissue 
culture cells have shown that oligodendrocytes, the myelinating cells of CNS, can be 
dysfunctional and abnormal Plp1 trafficking in the endoplasmic reticulum (ER) of 
oligodendrocytes can lead to apoptosis by activation of the unfolded protein response (UPR) 
(Dhaunchak and Nave, 2007; Elitt et al., 2018; Kramer-Albers et al., 2006). These studies 
suggest deficiencies in oligodendrocyte survival rather than problems of myelin composition with 
mutant PLP1. The involvement of ER stress and activation of the UPR could be confirmed in 
human oligodendrocyte cell models which were derived from patients’ iPSCs (Nevin et al., 2017; 
Numasawa-Kuroiwa et al., 2014). Of note, a recent study demonstrated that only a subset of 
PLP1 mutations show activation of an UPR in patient iPSC-derived oligodendrocytes (Nevin et 
al., 2017). Together with the lack of a consistent genotype-phenotype correlation in patients this 
result suggests the existence of additional pathobiological mechanisms that lead to 
dysfunctional oligodendrocytes or myelin formation in PMD. Here, we therefore investigated the 
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cell biological consequences of PLP1 mutations in greater detail using patient iPSC-derived 
oligodendrocytes and genetically corrected controls as a model system. 
 
RESULTS 
PLP1G74E mutant oligodendrocytes develop but subsequently die and cannot properly 
differentiate into myelinating cells.  
To generate human cellular models of PMD we initially obtained a skin biopsy from a 
PMD patient with early-severe PMD who presented with nystagmus, respiratory distress, loss of 
developmental milestones, spasticity and hypomyelination (Gupta et al., 2012). Genotyping 
revealed a point mutation in PLP1 gene at G74E (hereafter PLP1G74E mutation), which causes a 
single amino acid change from glycine to glutamic acid in the second transmembrane domain 
(Fig. 1A,C). We generated patient iPSC lines by episomal reprogramming (Diecke et al., 2015) 
that showed typical features of pluripotency (expression of OCT4, TRA 1-60 and generation of 
mature teratomas) and normal karyotype (Supplementary Fig. 1A-C).  
To assess potential phenotypic abnormalities in patient-derived oligodendrocyte 
precursor cells (OPCs), we adapted an established protocol (Supplementary Fig. 2A) (Douvaras 
and Fossati, 2015). Oligodendrocyte differentiation of these lines evidenced significant clone-to-
clone variability (Supplementary Fig. 2B), prompting us to develop line-specific isogenic controls 
for this study. To that end, we corrected the PLP1 G74E mutation in this patient’s iPSCs using 
adeno-associated virus-mediated homologous recombination (Supplementary Fig. 2D). 
Reassuringly, PMD mutant and gene-corrected iPSCs now showed similar differentiation 
dynamics as determined by appearance of neural rosettes and SOX1, PAX6, NKX2.2, OLIG2, 
and PLP1 expressing cells (Supplementary Fig. 2E) and reduced variability in oligodendrocyte 
generation within subclones (clonal lines obtained from single colonies after gene-correction of 
a parental clone) (Supplementary Fig. 2C). Expression of O4, a marker of oligodendrocytes at a 
pre-myelinating stage with immature morphology, first appeared around day 35 (D35) in both 
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mutant and corrected cells and increased subsequently (Supplementary Fig. 2F). Although on 
D45 numbers of mutant and corrected O4+ cells were similar (Fig. 1D-E,H), by D55 we 
observed significant losses of O4+ mutant cells compared to isogenic controls (Fig. 1F-G, H, 
Supplementary Fig. 2G). The onset of this phenotype was accompanied by induction of the 
mutant PLP1 protein in mutant cells at around D45 (Supplementary Fig. 2F). Remaining O4+ 
mutant cells failed to differentiate into MBP+ cells with mature and ramified oligodendrocyte 
morphology (Fig. 1K-P) and did not acquire robust expression of the mature marker myelin 
basic protein (MBP) (Fig. 1F-G, I). While we found about twice as many Caspase-3 positive 
mutant cells on D55, indicating apoptosis, this mechanism alone did not account for the 
observed 5-fold levels of cell attrition, and suggested additional mechanisms of cell death (Fig. 
1J, Supplementary Fig. 2H). 
Next, we sought to test the myelination capacity of human PMD mutant and gene-
corrected OPCs. When plated on previously established human fetal brain slice explant cultures 
(Fig. 2A see Methods) (Hansen et al., 2010) and analyzed at the limit of culture duration (3 
weeks), mutant cells failed to acquire mature oligodendrocyte morphology or expressed minimal 
level of MBP, contrasting the gene-corrected cells (Fig. 2, B-D). We then transplanted mutant 
and corrected OPCs into the brains of immunocompromised Shiverer (Shi) mice, which lack 
compact myelin due to disruption of the Mbp gene and die at around 16 weeks of age (Roach et 
al., 1983). We purified iPSC-derived OPCs by O4+ antibody-based immunopanning (Harrington 
et al., 2010) (Fig. 2E) and transplanted them into the cerebellum of Shi mice at postnatal day (P) 
1. Unlike mutant cells, 13 weeks post-transplantation near animal’s death, corrected human 
OPCs migrated from the injection site and differentiated into robustly MBP+ oligodendrocytes 
that exhibited a typical morphology with membrane ensheathment of multiple axons (Fig. 2F,H; 
Mean MBP+/human specific marker+ cells per unit area: mutant 0.875 ± 0.295, corrected 8.125 
± 0.990, t-test p = 0.0003). Electron microscopic analysis showed restoration of compact myelin 
in areas transplanted with corrected cells (G-ratio 0.8453 ± 0.02878), but not with mutant (G-
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ratio 0.9238 ± 0.00975, t-test p = 0.0039) (Fig. 2I-J). In contrast, most mutant cells even failed to 
survive in the host brain (Fig. 2G). Thus, the PLP1G74E mutation rendered oligodendrocytes 
unable to survive or achieve terminal differentiation in vitro, in explant slices ex vivo or in mouse 
brain in vivo.  
 
Lack of ER stress and unfolded protein response in PLP1G74E mutant cells. 
ER stress and activation of the UPR pathway leading to apoptosis is implicated for PLP1 
mutations in mouse models (Dhaunchak and Nave, 2007; Elitt et al., 2018; Kramer-Albers et al., 
2006; Numasawa-Kuroiwa et al., 2014; Southwood et al., 2002) (but also see (Nevin et al., 
2017)). Because conventional apoptosis could only partially explain observed cell death (see 
above), we next investigated the underlying mechanisms of the survival and differentiation 
deficiency of PMD mutant cells. Surprisingly, we found that UPR/ER stress pathway genes were 
not activated in purified human O4+ cells from the PLP1G74E mutant oligodendrocytes (Fig. 3A). 
We also did not observe accumulation of the PLP1G74E mutant protein in the ER, instead found it 
extensively dispersed from the ER into the fine processes of the cell (Fig. 3C,E, G-L). We could 
find only rare examples of mutant PLP1 protein that co-localized with the ER marker KDEL (Fig. 
3B,D, F), indicating ER retention was minimal. We tested inhibitors of the ER stress pathways 
but these did not rescue survival PLP1G74E mutant oligodendrocytes in culture (Supplementary 
Fig. 3A). Finally, transplanted mutant OPCs did not express the ER stress marker CHOP protein 
in vivo (Supplementary Fig. 3B). Together, these findings indicated that cell death of PLP1G74E 
mutant OPCs did not involve significant UPR or ER stress pathway activation, and suggested 
additional pathobiological pathways.  
 
Accumulation of oxidative species and activation of oxidative stress genes in PLP1G74E 
mutant oligodendrocytes. 
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Oxidative stress is a common pathogenetic mechanism in many neurological disorders. 
Indeed, purified PLP1G74E mutant OPCs showed strong induction of several oxidative stress 
marker genes when compared to gene-corrected OPCs (Fig. 3M). Moreover, mutant cultures 
more strongly labeled with CellROX, a dye that detects reactive oxygen species (ROS) in live 
cells, compared to gene-corrected cultures, and a higher fraction of mutant OPCs was labeled 
with the dye (Fig. 3N-P). We conclude that the PLP1G74E mutation induced high oxidation levels 
in OPCs. The potential causes of increased oxidation are manifold and we therefore continued 
to search for additional pathological abnormalities in mutant cells. 
 
Marked deregulation of iron metabolism in human PLP1G74E mutant oligodendrocytes 
Rodent oligodendrocytes express high levels of transferrin (TF) (Espinosa de los 
Monteros et al., 1999; Leitner and Connor, 2012; Zhang et al., 2014), the major iron transporter 
for intracellular uptake of iron (Brissot and Loreal, 2016; Hentze et al., 2010). We confirmed 
similar findings in human cells, relatively high TF expression in primary fetal human O4+ 
oligodendrocytes (Fig. 4A-D) compared to other neural cells (Fig. 4E) and increased levels of 
oxidative stress genes (Fig. 4F). Dysregulation in iron metabolism can pose oxidative stress for 
which oligodendrocytes are particularly vulnerable (Back et al., 1998; Butts et al., 2008; 
Khorchid et al., 2002). We therefore investigated whether iron metabolism was dysregulated in 
PMD mutant cells. Expression profiling showed several iron regulation genes were indeed 
significantly de-regulated including transferrin itself (Fig. 4I). To further corroborate these 
findings, we performed quantitative immunoblotting of some key iron regulatory proteins. 
PLP1G74E mutant OPCs showed a consistent downregulation of TF (iron transporter) and ferritin 
(iron storage), and up-regulation of the iron regulatory protein 1 (IRP1) (Fig. 4J). Flow cytometric 
analysis of mutant and corrected oligodendrocytes revealed about a two-fold upregulation of the 
transferrin receptor (Fig. 4G-H, Supplementary Fig. 4A).  
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Human PLP1G74E mutant oligodendrocytes exhibit hallmarks of ferroptosis: iron-toxicity 
and lipid-peroxidation. 
Having observed a dysregulation of key iron metabolism regulatory proteins, we sought 
to explore potential functional consequences of these expression changes. To investigate the 
role of TF and free iron, we differentiated mutant and corrected iPSCs without additional TF, 
with addition of (iron-free) apo-transferrin (TF) or (iron-bound) holo-TF from days 35 to 55. This 
is the time frame in which mutant oligodendrocyte cell death begins and PLP1 protein 
expression is initiated (Supplementary Fig. 2F). Remarkably, addition of apo-TF to the media 
completely restored mutant oligodendrocytes’ viability to the level of genetic rescue (Fig. 5A-
F,K). Apo-TF is a central extracellular iron transporter and has high affinity for free iron; thus, it 
effectively reduces free extracellular iron concentration as a chelator while making it available to 
cells as holo-TF via TF receptors. Because addition of holo-TF did not have beneficial effects 
(Fig. 5C-D,K) we deduced that the rescue is caused by the effective decrease of the 
extracellular iron concentration rather than making more iron available to cells. This conclusion 
is corroborated by our observation that the two FDA-approved small molecule iron chelators 
deferoxamine (DFO) and deferiprone (DFP) rescued mutant cells just as Apo-TF treatment did 
(Fig. 5G-H,K Supplementary Fig. 4B-C). Elevating the extracellular iron concentration reversed 
effects of apo-TF in mutant cells suggesting an iron-specific effect (Fig. 5I-K). Indeed, no other 
divalent transition metal ions tested led to increased apoptosis or halted differentiation in mutant 
or corrected oligodendrocytes (Fig. 5L-M). We further found that Apo-TF, DFO, or DFP 
treatment normalized the overall number of O4+ cells, apoptosis, and differentiation into MBP+ 
cells (Supplementary Fig. 4B-E). Of note, Apo-TF treatment had no significant effect on gene-
corrected control oligodendrocytes suggesting that the PLP1G74E mutation increased the 
sensitivity to iron in oligodendrocytes (Fig. 5F,K).  
            Iron-mediated cell death can be due to ferroptosis, which comprises iron-toxicity and 
iron-dependent lipid peroxidation (Dixon et al., 2012). We found that PLP1G74E mutant 
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oligodendrocytes undergo increased oxidative stress and discovered that iron chelation 
normalizes ROX, an oxidation-sensitive dye in live cells (Supplementary Fig. 4F). To more 
specifically assess whether cells undergo lipid peroxidation, we optimized an assay for 
accumulation of lipid ROS for our oligodendrocyte cultures (Naguib, 1998). Indeed, PLP1G74E 
mutant cultures showed both general and oligodendrocyte-specific increase in lipid ROS, 
suggesting peroxidization of cellular lipids during differentiation (Fig. 5N-P). We noted that not 
all mutant cells showed accumulation of lipid ROS (<60% of O4+ cells), and together with the 
evidence for Caspase-3 dependent apoptotic cell death in about 40% of O4+ cells (Fig. 1J), we 
conclude that multiple modes of cell death were at work. Further studies are needed to confirm 
that lipid ROS production lies downstream of iron induced toxicity in oligodendrocytes affected 
by PMD that are rescued by chelation. 
          As shown (Fig. 5P), addition of Apo-TF and DFO reduced lipid ROS+ cells to wild type 
levels indicating that lipid peroxidation was iron-dependent. We next used a series of lipophilic 
and hydrophilic antioxidants to assess whether the lipid ROS is responsible for the mutant 
oligodendrocyte phenotype. Compared to hydrophilic antioxidants GSH and NAC, lipophilic 
antioxidants BHT and Trolox rescued oligodendrocyte differentiation and/or apoptosis (Fig. 5Q-
R Supplementary Fig. 4G), supporting lipid ROS as the key inducer of mutant oligodendrocyte 
death. These findings indicate that the PLP1G74E mutation renders oligodendrocytes more 
sensitive to extracellular free iron, which leads to elevated lipid peroxidation, block of 
differentiation and cell death – all key hallmarks of ferroptosis-mediated cell death.  
 
Iron chelation rescues survival and maturation of transplanted human PLP1G74E mutant 
oligodendrocytes in mouse brains and human brain slices. 
We next asked whether iron chelation would promote survival and differentiation of human 
PLP1-mutant OPCs in vivo. We tested whether O4+ mutant cells, grown in conditions of iron 
chelation, had enhanced survival and/or myelinating capacity in vivo. O4+ cells were purified 
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and transplanted into the cerebellum of immunocompromised Shi mice (Fig. 6A).  Mutant 
human OPCs pre-treated with apo-TF or DFO from D35-55 of the differentiation protocol readily 
engrafted and gave rise to mature MBP+ cells, in contrast to untreated cells (Mean 
MBP+/human specific marker+ cells: untreated 0.875 ± 0.295, apo-TF treated 8.80 ± 1.20, DFO 
treated 8.40 ± 1.470, One-way ANOVA p < 0.0001) (Fig. 6B-D). Ultrastructural analysis showed 
multilayer ensheathment of axons by mutant apo-TF- (G-ratio 0.8318 ± 0.02442, p = 0.0008) or 
DFO-treated (G-ratio 0.8388 ± 0.0155, p = 0.0013) but not untreated cells (G-ratio 0.9238 ± 
0.009750, One-way ANOVA p = 0.031) (Fig. 6E-G). Similarly, when mutant oligodendrocytes 
were pre-treated with apo-TF or DFO for 7-10 days and then placed on human fetal brain slice 
cultures, they showed a substantially improved differentiation (Fig. 6H-L). Thus, iron chelator 
pre-treatment of mutant O4+ OPCs enhanced survival and differentiation in mouse brain in vivo.  
 
Iron chelation rescues additional PLP1 mutations in human and mouse 
oligodendrocytes. 
Our findings with the PLP1G74E mutation raised the question whether iron sensitivity is a more 
common phenomenon in other PLP1 PMD-relevant mutations. To address this question we 
generated OPCs from PMD patients carrying a PLP1T75P point mutation (Gupta et al., 2012), 
another point mutation PL1F233L resulting in exon 6 deletion (Nevin et al., 2017), and PLP1 
duplication (Nevin et al., 2017). Remarkably, the PLP1T75P point mutation and the duplication, 
but not the exon 6 mutations were also rescued by the iron chelation (Fig. 7A-G). We also 
investigated the severe PMD Jimpy mouse model that harbors a Plp1 point mutation that affects 
the splicing of exon 5 (Dautigny et al., 1986; Sidman et al., 1964). While untreated mutant 
primary Jimpy OPCs in vitro showed inhibited differentiation block and nearly universal cell 
death within 24 hours of growth factor withdrawal (Fig. 7H-I, K-L), 4-day treatment with DFO 
rescued both parameters to near wild type OPC levels (Fig. 7J-L). These results demonstrate 
that the ferroptosis-mediated oligodendrocyte death is not restricted to the PLP1G74E mutation 
Nobuta, et al.  
 11 
and extends to other PLP1 mutations. Overall, four out of five PLP1 mutations tested showed a 
rescue by iron chelation. Of note, ferroptosis activation is not mutually exclusive with induction 
of ER stress since the Jimpy and other Plp1 mutations are known to cause a severe UPR 
activation (Dhaunchak and Nave, 2007; Ikeda et al., 2016; Kramer-Albers et al., 2006).  
 
Systemic treatment of Jimpy mice with Deferiprone results in enhanced oligodendrocyte 
survival and new myelin formation. 
 The successful rescue of Jimpy oligodendrocytes in vitro raised the question whether 
iron chelation may also improve the disease progression in vivo. The Plp1 Jimpy mutation 
causes a very aggressive disease; mice do not show any myelin formation, develop severe 
seizures by postnatal week 3, and die around P28 (Dautigny et al., 1986; Sidman et al., 1964). 
We systemically administered a blood brain barrier-permeable iron chelator DFP to Jimpy mice 
from P7-14 and P21-28 by i.p. injections (Fig. 7M). A 1-week long interruption (P14-P21) was 
introduced to prevent anemia (Supplementary Fig. 5D). As shown in Fig. 7N-Q’, DFP treatment 
substantially reduced levels of apoptosis in corpus callosum in Jimpy mice (45.63 ± 5.61% 
reduction from vehicle, t-test p >0.001), and allowed the formation of new myelin in the corpus 
callosum as determined by electron microscopy at P28. In addition, astrogliosis and microglia 
activation in the white matter were both reduced (Supplementary Fig. 5E). We also observed a 
slight improvement of overall animal survival (Supplementary Fig. 5C). Notably, a seven-day 
course of DFP treatment was sufficient to significantly reduce the UPR/ER stress markers Atf4, 
phosphorylated Eif2D, and Chop (Elitt et al., 2018) in Jimpy OPCs and mature oligodendrocytes 
in vivo (Fig. 7R-W, Supplementary Fig. 5G-J). These findings indicate that ferroptosis-like stress 
also influences the UPR/ER pathway in Jimpy, a severe PMD mutation, and that iron chelation 
substantially rescues this pathophysiology.  
 
 




Our findings highlight dysregulation of iron metabolism as a significant pathobiological 
mechanism mediating OPC cell death in severe PMD models. We found evidence for ferroptotic 
as well as apoptotic cell death mechanisms in PMD oligodendrocytes. Both human and mouse 
PMD OPCs showed a decrease of transferrin, ferritin, iron export proteins APP and CP, and 
increased or unchanged IRP1/2 and transferrin receptor expression. While indicating a 
dysregulated iron metabolic response, the condition of PMD oligodendrocytes is distinct from 
classic iron overload in hemochromatosis where increased hepatic intracellular iron is 
associated with high ferritin and ferroportin and low levels of transferrin receptor (Recalcati et 
al., 2006; Siah et al., 2005). Consistent with ferroptosis, PMD oligodendrocytes exhibited lipid 
peroxidation and phenotypic rescue by iron chelation (Fig. 5N,P) (Dixon et al., 2012). However, 
we also found that apoptosis marker Caspase-3 was enriched among some mutant cells and 
that iron chelation also normalized Caspase-3 levels to control levels (Fig. 5L). Similarly, we 
observed a reduction of ER stress and apoptosis in Jimpy oligodendrocytes rescued by DFO 
(Fig. 7R-W, Supplmentary Fig. 5G-J). These data suggest that the severe iron sensitivity we 
observed in PMD oligodendrocytes involve various cell pathogenetic mechanisms of iron-
induced ferroptosis, ER stress (Feng and Stockwell, 2018) and apoptosis and that these 
pathways in some PMD lines are benefitted by chelation. We conclude that mechanisms of Fe-
induced cell death in PMD oligodendrocyte are complex, and that further studies are needed to 
define precise pathway interactions in a patient/mutation-specific manner. 
 A recent publication described a drug screening platform based on cultured Jimpy 
oligodendrocytes and found the small molecule Ro 25-6981, a N-methyl-D-aspartate 
(NMDA) receptor antagonist, to enhance survival (Elitt et al., 2018). While the functional target 
of Ro 25-6981was independent of NMDA receptor, authors showed its modulatory effects on 
UPR signaling and subsequent increase in myelin in Jimpy mice. DFP is a FDA-approved drug 
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for clinical use in pediatric population thus a viable treatment option for PMD. As shown in Jimpy 
mice, DFP significantly reduced ER stress/UPR markers, suggesting the beneficial effect of 
DFP in PLP1 mutations that lead to ER stress/UPR. In contrast, most ER stress/UPR inhibitors 
(Maly and Papa, 2014) and Ro 25-6981 are not approved for clinical use, and administration of 
NMDA receptor antagonist (Ro 25-6981) to infant patients whose CNS is still developing may 
not be ideal.  
Unlike gene and cell therapeutic approaches (Gupta et al., 2012), iron chelation aims to 
support endogenous mutant OPC survival through the “critical window” of transition from pre-
myelinating to myelinating stages. Indeed, we found that pre-transplant iron chelation was 
sufficient to promote survival and myelination of mutant oligodendrocytes in human slice culture 
and in vivo for several months post-transplantation in Shiverer mice (Fig. 6A-F). For both slice 
culture system and in vivo transplantation, we characterized the myelin at the limit of the culture 
duration (3 weeks) or at the end of the lifespan of the Shiverer hosts (about14-16 weeks) (Fig. 
6A-F, H-L). Up to these points, we observe myelin formation by EM. This suggests that PMD 
oligodendrocytes are most vulnerable to iron-induced toxicity during dynamic differentiation at 
the onset of mutant PLP1 expression. While our findings suggest that DFP could be an 
appropriate therapy for selected PMD patients, it will be important to optimize drug dosage, 
timing for administration and the long-term benefit to oligodendroglial survival and myelination. 
Evidence in the literature suggests the involvement of iron pathobiology in multiple sclerosis and 
neurodegeneration with brain iron accumulation, (Hayflick et al., 2006; Kruer et al., 2010; 
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Figure 1. PMD oligodendrocytes die prematurely and fail to differentiate with ramified 
morphology. A, Three G74E, T75P, and F233L point mutations in PLP1 described in this paper 
are located in the second transmembrane domain or extracellular domain. An additional 
duplication mutation as well as a mouse point mutation (Jimpy mouse) were investigated in this 
study. B, Gene targeting strategy to correct the G74E point mutation in exon 3. The targeting 
vector was cloned into an adeno-associated virus (AAV) vector along with neomycin resistant 
cassette flanked by loxP sites. Pink bars represent locations for homologous recombination. 
The neomycin cassette was removed by a transient Cre transfection. C, Sanger sequencing 
validated the accurate correction. D-E, On D45, mutant and corrected iPSCs had differentiated 
to normal-appearing O4+ OPCs. F-G, On D55, the mutant cells were fewer, morphologically 
simpler, and expressed minimum levels of the maturation marker MBP. H, Quantification of O4+ 
cells by flow cytometry on D45 and D55 showed progredient loss of cells (N=3-5, biological 
replicates). I, Immunofluorescent quantification of MBP+/O4+ cells at D55 showed a 
differentiation block of mutant cells (N=3-4, biological replicates). J, PLP1 mutant cells showed 
an increased fraction of Caspase-3+/O4+ cells at D55 (N=3-4, biological replicates). K-P, 
Assessment of morphological complexity in O4+ cells using Sholl analysis software. 
Immunofluorescent images of O4+ cells were captured, then individual cell morphology was 
reconstructed by tracing the O4 stained branches assisted by Fiji plugin software Simple Neurite 
Tracer. Quantification showed failure of the mutant cells to achieve time-dependent increase in 
total traced length and ramification index (N=11-18 cells/treatment).  
 
Figure 2. Gene correction in PLP1G74E mutation rescues oligodendrocyte differentiation 
and axonal myelination. A, Schematic of co-culture system of human brain slice and EGFP-
labeled, iPSC-derived OPCs. B, At 21 days after co-culture, iPSC-derived gene corrected 
oligodendrocytes (EGFP+/MBP+) showed similar morphologies as endogenous oligodendrocytes 
(EGFP-/MBP+). C, Classification of MBP+ cells based on morphological complexity. D, PLP1G74E 
mutant oligodendrocytes had mostly abnormal or immature morphologies (N=6-9 slices/ group, 
total number of transplanted oligodendrocytes pooled for analysis). E, For in vivo 
transplantation, O4+ OPCs were purified by removal of lectin+ nonspecific cells, followed by O4 
immunopanning. Cells were transplanted into the cerebellum of postnatal immune-deficient 
Shiverer mice (N=3-4). F, MBP (green) and the human-specific antibody STEM121 (red) 
detected many corrected iPSC-derived oligodendrocytes after transplantation. G-H, Corrected 
cells engrafted and efficiently differentiated to MBP+ oligodendrocytes whereas transplanted 
PLP1G74E mutant cells failed to survive in the host brain. I, Electron microscopy of the 
transplanted area. Only thinly and loosely myelinated axons were found in Shiverer mouse 
transplanted with PLP1G74E mutant cells. J, Electron microscopy of area transplanted with 
corrected cells revealed multi-layer, compact myelin. 
 
Figure 3. Lack of evidence for ER stress, and evidence for abnormal iron metabolism and 
oxidative stress in in PLP1G74E mutant OPCs. A, qPCR quantification of UPR and ER stress 
genes in PLP1G74E mutant and corrected OPCs showed no significant difference with corrected 
cells (N=3-4, biological replicates). B,D, Little co-localization of mutant PLP1G74E protein and the 
ER marker KDEL (arrows). C,E, Instead PLP1G74E localized to fine processes (arrowheads) 
similar to wild type PLP1 in corrected cells (N=9 fields/group). F, Quantification of overlapping 
(colocalizing) staining with KDEL and PLP1 showed a trend but no significant difference 
between PLP1G74E mutant and gene corrected oligodendrocytes. G-L, Evidence of PLP1G74E 
protein transported out of ER to near O4+ cell surface locations. M, Induction of oxidative stress 
genes in PLP1G74E mutant cells revealed by qPCR (N=4-5, biological replicates). N-P, Increased 
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levels of oxidative species in live OPCs detected with CellROX dye at D55 of differentiation 
(N=3, biological replicates).  
 
Figure 4. Unique iron regulation and oxidative stress in human oligodendrocytes and 
PLP1G74E mutation. A-C, Schematic of human oligodendrocyte isolation. Left: The brain tissue 
is dissociated into single cells, passed through lectin (BSL) and mouse IgM secondary antibody-
coated plates to remove non-specific cells. O4+ oligodendroccytes are then positively selected 
by attaching them to O4 coated plate. D, Isolated cells bound to O4 antibody showed other 
markers of oligodendrocyte markers such as OLIG2 and PDGFRD. E, qPCR quantification of 
iron regulatory genes in human endogenous O4+ oligodendroccytes vs the rest of the neural 
cells unbound to the O4 antibody revealed an exceptionally high TF expression in 
oligodendrocytes. F, Quantification of oxidative stress gene expression in human O4+ 
oligodendrocytes vs the rest of the neural cells by qPCR revealed naturally high level of 
oxidative stress in healthy human oligodendrocytes. G, Representative flow cytometry plot 
quantifying the level of TF receptor (TFRC) in O4+ OPCs. H, Increased surface expression 
TFRC in mutant OPCs determined by flow cytometry (N=3-7, biological replicates). 
I, Abnormal expression of iron regulatory genes in mutant OPCs by qPCR (N=3-4, biological 
replicates). J, Western blot analysis of iron regulatory proteins (two pooled samples of N=3-4 
biological replicates).  
 
 
Figure 5. Iron chelation and lipophilic antioxidants rescue mutant cell survival and the 
differentiation block. A-D, In the baseline amount of TF or in the presence of iron-bound holo-
TF, PLP1G74E mutant O4+ cells degenerated on D55. E-F, Reduction of free iron by apo-TF 
addition inhibited PLP1G74E mutant O4+ cell death but had no effect on corrected cells. G-J, 
Reduction of iron by the iron chelator deferoxamine (DFO) in presence of holo-TF also blocked 
cell death, similar to apo-TF. Additional iron administration counteracted the apo-TF effects. K, 
Quantification of O4+ cells in all treatment groups by flow cytometry (N=3-4, biological 
replicates). L-M, Quantification of cell death and OPC differentiation in O4+ cells.  N-P, 
Increased lipid ROS level in PLP1G74E mutant cells was rescued by the presence of apo-TF or 
DFO to the levels of corrected cells (N=3-4, biological replicates). Q-R, Immunofluorescence 
quantification of MBP/O4+ cells revealed that only the lipophilic antioxidants BHT or Trolox but 
not the hydrophilic antioxidants GSH or NAC, rescued the differentiation defect of PLP1G74E 
mutant cells (N=3-4).  
 
Figure 6. Iron chelation rescues phenotypes of PLP1G74E mutation post transplantation 
and in slice explant culture. A, PLP1G74E mutant and corrected OPCs were transiently (D35-
55) treated with apo-TF or DFO before transplantation into the Shiverer mouse. B-D, Whereas 
untreated PLP1G74E mutant OPCs failed to survive in the host brain, transient DFO and apo-TF 
treated OPCs survived and differentiated to mature MBP+ oligodendrocytes (N=3). E-G, 
Ultrastructural assessment showed rescue of multi-layer myelination by the apo-TF and DFO-
treated PLP1G74E mutant OPCs. H, Schematic of treatment regimen of human slice co-cultures 
with DFO or apo-TF. I-K, Transient and long-term iron chelation rescued the differentiation block 
of PLP1G74E mutant OPCs as seen by MBP staining of EGFP+ cells (4-8 slices/treatment group, 
total number of transplanted oligodendrocytes pooled for analysis). L, Quantification of 
differentiation classes used the same criteria as in Fig. 2C-D. 
 
Figure 7. Iron chelation rescues phenotypes of multiple PLP1 mutations in vitro and in 
vivo. A, Treatment strategy to assess effects of DFO in additional human PMD mutations. B-G, 
Differentiation phenotype of additional human PMD mutations after treatment with DFO (N=3-4, 
biological replicates). B&E = T75P point mutation, C&F = Exon6 deletion, D&G = Duplication. H, 
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Jimpy mouse OPCs isolated at postnatal day 5-8 were tested for differentiation phenotype and 
transiently treated with iron chelation. I-J, Jimpy OPCs completely failed to differentiate upon 
removal of growth factors which was associated with increased cell death. K-L, Transient (4 
day) DFO treatment rescued both differentiation and cell death as measured by Caspase-3 and 
MBP expression (N=10 fields/treatment from 2 biological replicates). M, In vivo iron chelation 
strategy in Jimpy mice. Subcutaneous injections with the brain-permeable iron chelator 
deferiprone (DFP) were given from postnatal day 7-14 and 21-death. N-O, Corpus callosum of 
vehicle-treated Jimpy mice at postnatal day 28 showed Caspase-3+ apoptotic cells.  P-Q, 
Electron microscopic analysis of corpus callosum in DFP- and vehicle-treated Jimpy mice 
showed surviving oligodendrocytes in the DFP-treated mice. Higher magnification of P and Q 
are depicted in P’ and Q’, respectively. R-W, Fluorescent in situ hybridization (RNA scope) 
showed a significant reduction in Atf4 and Chop gene expressions in Mbp+ mature 
oligodendrocytes after a 7-day in vivo DFP treatment from P7 in Jimpy mice (N = 3-4). X-Y, 
Immunostaining for Chop after a 7-day in vivo DFP treatment from P7 revealed a reduction in 
colocalization with pan-oligodendrocyte marker Olig2. Z, Western blot analysis of Jimpy brain 
showed significant reductions in UPR/ER stress markers Atf4 and phosphorylated Eif2Din DFP-
treated Jimpy mice. 
 
Supplementary Figure 1. Validation of pluripotency and normal karyotype in PLP1G74E 
patient and corrected iPSCs. A, Subcutaneous injection of iPSCs in immunodeficient mice 
resulted in teratoma with three germ layers: ectoderm, endoderm, mesoderm. B, iPSCs express 
pluripotency markers OCT4 and TRA1-160 at the protein level. C, Both patient and corrected 
iPSCs show normal karyotype. 
 
Supplementary Figure 2. Oligodendrocyte differentiation kinetics of PLP1 mutants and 
corrected iPSCs. A, Schematic of oligodendrocyte differentiation protocol. B, An example of 
large variability among three original iPSC lines generated simultaneously from a patient with 
PLP1T75P mutation, and their response to apo-TF and DFO. Clone 4 naturally made 
oligodendrocytes in response to standardized protocol, but clone 1 and 5 generated minimal 
number of oligodendrocytes. C, Two left data sets show six original iPSC clonal lines generated 
from a patient with PLP1G74E mutation and their response to DFO treatment showing large 
variability, resulting in non-significant difference. Five datasets to the right show the phenotypic 
results of the clone 3 used in the gene correction to WT PLP1 sequence that generated multiple 
subclones (3 shown here) that share the same culture history, which resulted in a much smaller 
variability. D, (Left) Validation of a single genomic integration of the targeting construct by 
Southern blot. Lane 1 shows a single band of an appropriate size. (Right) Detailed targeting 
construct design for PLP1G74E mutation. The mutant endogenous sequence contained a single 
base pair mutation in exon3. The targeting construct with homologous arms shown in gray 
contained wildtype sequence for correction purpose. It also contained neomycin resistant gene 
flanked by loxP sites for drug screening purpose. The targeting construct was cloned into AAV 
vector. After drug selection, targeted locus was sequenced using PCR product, which was 
amplified with primer pairs shown in pink and green. These primer pairs distinguish endogenous 
vs targeted sequence by amplifying a fragment containing human genomic DNA and newly 
introduced neomycin resistant gene. Homologously targeted clones were then transiently 
transfected with Cre recombinase to remove neomycin cassette. E, Initial phase of 
oligodendrocyte differentiation in both PLP1G74E mutant and corrected cells are similar, 
assessed by iPSC morphology (D0), SOX1+/PAX6+ neural rosette formation (D7), and 
NKX2.2+/OLIG2+ oligodendrocyte precursors (D11). F, Onset of PLP1 protein expression in O4+ 
cells occurs between day 35 and 45. G, Representative FACS plots for quantification of O4+ 
cells. H, Representative images of Caspase-3, colocalizing with O4+ OPCs in PLP1G74E. 
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Supplementary Figure 3. Lack of rescue in PLP1G74E OPCs by UPR/ER stress inhibitors. 
A, ER stress inhibitors GSK2656157 or Kira6 was added to the culture and surviving O4+ cells 
were quantified. The treatment did not rescue the mutant phenotype (N=3). B, Staining for ER 
stress marker CHOP in Shiverer mouse 12 weeks after transplantation of mutant cells shows no 
colocalization with transplanted oligodendrocytes (MBP+).  
 
Supplementary Figure 4. Iron chelation treatment rescues defective mutant OPC 
differentiation. A, Representative FACS plot for transferrin receptor in O4+ oligodendrocytes. 
B-C, In addition to DFO treatment shown in Fig. 5 G-H, an additional iron chelator deferiprone 
showed beneficial effects in the reduction of Caspase-3+ OPC cell death and increase in MBP+ 
differentiation in the mutant cells (N=3). D-E, Quantification of OPC cell death and differentiation 
in presence of treatment by apo-TF and DFO (N=3-4). F, Quantification of lipid ROS assay, in 
presence of chelation treatment by apo-TF and DFO (N=3-4). G, Out of the two lipophilic 
antioxidants BHT and Trolox that showed efficacy in rescuing mutant OPC differentiation, Trolox 
also reduced mutant cell death. A lipid oxidizing agent cumene hydroperoxide reversed the 
beneficial effect by apo-TF (N=3-5). 
 
Supplementary Figure 5. In vivo Iron chelation rescues Jimpy oligodendrocytes. A-B, 
Representative images of WT and Jimpy primary OPCs treated with vehicle or DFO. C, Kaplan-
Meyer survival curve of DFP-treated Jimpy mice shows a significant increase of lifespan by DFP 
treatment (p = 0.047, N=7 treated group, N=11 untreated group). D, Complete blood counts 
(CBC) for determination of DFP dose. All parameters in CBC showed a dose-dependent anemic 
effect. A clinically relevant 30mg/kg was chosen with one week break for DFP in vivo 
experiment. E, Brains of Jimpy mice treated with vehicle or 30mg/kg/day DFP were collected at 
postnatal day 28 and cerebellar white matter was analyzed for reactive astrocytes (GFAP) and 
microglia (Iba1) activation. F, Quantification showed a significant reduction in inflammatory 
response in DFP-treated mice (N=3). G-J, Fluorescent in situ hybridization (RNA scope) 
showed a significant reduction in Atf4 and Chop gene expressions in PDGFRD+ OPC after a 7-
day in vivo DFP treatment from P7 in Jimpy mice (N = 3-4). 
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iPSC generation and culture 
Fibroblasts from two PMD patients enrolled in a clinical study (Clinicaltrials.gov identifier 
NCT01005004) were obtained under approval from UCSF Institutional Review Board (IRB) 
(Study Protocol13-10806). All iPSC lines were established by electroporation of a CoMiP 
episomal vector containing 4 reprogramming factors (OCT4, KLF4, SOX2, and c-MYC) following 
a published protocol1.  
iPSCs were maintained on CF1 MEF feeder cells in ES medium containing Knockout 
DMEM/F12, 20% knockout serum replacement, non-essential amino acids, Glutamax (Life 
Technologies), and 10ng/ml human basic FGF (peprotech). Pluripotency was confirmed by 
expression of TRA1-60 (Cell Signaling), OCT3/4 (Santa Cruz Biotechnology), as well as 
teratoma formation and differentiation into ectoderm, mesoderm, and endoderm lineages. A 
normal karyotype was confirmed in all lines. Mycoplasma contamination has been confirmed 
negative in all iPSC lines. 
 
Gene targeting 
AAV plasmid and targeting vector design. 5’ homologous arm (1.2kb) containing wildtype PLP1 
exon 3 sequence, and 3’ homologous arm (1.3K) containing intron 3 sequence were amplified 
from genomic DNA of the patient’s father by PCR. A PGK promoter and neomycin resistance 
cassette flanked by two loxP sites was inserted between 5’ and 3’ homologous arms. Please 
see Extended Data Figure 14 for annotated complete sequence of the targeting vector. The 
construct was cloned into pAAV packaging plasmid.  
 
AAV viral preparation. AAV was produced using a highly recombinogenic AAV-DJ AAV 
serotype2 in HEK293T cells as described3. pAAV containing wildtype PLP1 sequence, pHelper, 
and pRC-DJ were co-transfected and three days later, HEK293T cells were collected, 
suspended in benzonase buffer, and subjected to 3 rounds of freeze-thaw cycles to homogenize 
the cells. Homogenate was incubated with benzonase to digest DNA, spun at 5000RCF for 
15min, and the supernatent containing AAV was used for iPSC infection. 
 
AAV transduction of iPSCs. iPSCs were infected by seeding 0.25×106 cells plated on to matrigel 
coated 6-well plate in NutriStem XF/FF Culture medium (Stemgent). One day after infection, 
medium was changed to ES cell medium and MEF feeder cells were added. Two to three days 
after infection, neomycin (100ug/ml) was added to the culture for approximately 1 week.  
 
Validation of targeting. Neomycin resistant iPSC colonies presumably incorporated the targeting 
vector were manually picked, expanded, and checked for homologous recombination by PCR 
using primers designed to detect recombination junctions spanning endogenous PLP1 allele 
and non-endogenous neomycin resistance gene, or PGK promoter. The primer locations are 
depicted in pink and green arrows in Extended Data Figure 3b. Following this initial PCR 
screen, the mutant locus was sequenced to confirm the gene correction to wildtype sequence. 
To exclude the possibility of multiple integrations, Southern blot analysis using a probe against 
neomycin resistance gene was performed. The 300bp probe template was obtained from 
digestion of the targeting pAAV plasmid with PSTI and SapI followed by gel extraction. The P32 
labeled probe was made with Klenow labelin kit (Agilent) and purified with microspin columns 
(GE Healthcare Life Sciences). 10ug of genomic DNA was digested overnight with EcoRI and 
separated by electrophoresis. DNA was blotted on to a nylon membrane and crosslinked. The 
neomycin probe was incubated for 3 hours at 65ºC. Following washes, signals were detected by 
autoradiography film (Kodak). After confirmation of a single integration of the targeting 
construct, the neomycin resistant gene was excised by transfecting a Cre expression plasmid 
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containing puromycin resistant gene with FuGENE6 (Promega). Three days post transfection, 
puromycin (1ug/ml) was added to the medium for 2 days to select Cre expressing colonies. 
Resistant colonies were picked and evaluated for neomycin sensitivity and loss of neomycin 




 A previously published protocol for directed iPSC differentiation to OPCs4 was used with 
the following modifications: human ES cell medium and human ES cell medium without basic 
FGF were used in place of mTeSR and custom mTeSR, respecitvely. The concentration of SAG 
was 0.5uM, T3 was 40ng/ml, NT3 was 1ng/ml. Penicillin-Streptomycin was omitted from N2 
medium, HGF from PDGF medium, and HEPES from Glia medium. When apo-TF or holo-TF 
was used in PDGF medium and Glia medium, commercially available N2 supplement (Life 
Technologies) was replaced with: 6.3ng/ml progesterone, 5.2ng/ml selenite, 16.11ug/ml 
putrescene, 5ug/ml human insulin, and 150ug/ml human TF (either apo- or holo- form, R&D).  
 On day 0, iPSCs between passage 18 and 20 were plated at 0.25X106/well on a 
matrigel-coated 6-well plate with ES medium without basic FGF, supplemented with dual SMAD 
inhibitors, RA, and ROCK inhibitor thiazovivin (Santa Cruz). From day 1 to day 4, N2 medium 
was gradually increased by 25% each day, reaching 100% on day 4. On day 8, dual SMAD 
inhibitors were replaced with SAG. On day 12, cells were lifted, dissociated, and seeded on petri 
dishes for sphere formation. On day 20, the medium was changed to PDGF medium. On day 
30, spheres were plated on poly-L-ornithine/laminin-coated plates. On day 45, the medium was 
changed to Glia medium. Most differentiation assays were conducted at day 55 unless 
otherwise stated.  
 
Small molecules and peptide treatments 
The following drugs were added to OPC differentiation culture from day 35 to 55: apo-TF (R&D 
3188-AT, 150ug/ml), holo-TF (R&D 2914-HT, 150ug/ml), deferoxamine (Sigma D9533, 10uM), 
deferiprone (Sigma 379409, 30uM), GSH (Sigma G4251, 1mM), NAC (Sigma A9165, 0.25mM), 
BHT (Sigma 47168, 100uM), Trolox (Sigma 238813, 60uM), cumene hydroperoxide 
(Component of Life Technologies C10446, 1:5000), Ferrostatin-1 (Tocris 5180, 300nM), 
Liproxstatin-1 (Sigma SML141, 300nM), RSL-3 (Cayman chemical 19288, 10nM), Ammonium 
iron citrate (Sigma F5879, 5ug/ml), Ferric citrate (Sigma F3388, 15uM), Manganase chloride 
(Sigma M8054, 15uM), Cobalt chloride (Sigma 255599, 15uM), Nickel Sulfate (Sigma 227676, 
15uM), GSK2656157 (EMD Millipore 5046510001, 200nM), Kira6 (from Papa lab, UCSF, 
50nM). 
 
In vivo Cell transplantation 
All data shown involving animal procedures were performed according to protocols approved by 
the Stanford University Institutional Animal Care and Use Committee. Initially, we transplanted 
unpurified neural progenitor cells at around days 60-80 of the differentiation protocol into 
Shiverer mice. However, the overproliferation presumably of more primitive cells complicated 
the analysis. We therefore purified O4+ cells at day 55 from the bulk culture by immunopanning 
(see method described below). 12,000 O4-immunopanned cells/site in 0.5ul volume were 
transplanted in postnatal day 1 of Shiverer;Rag2-/- mice. Site of transplantation was cerebellar 
white matter, identified by coordinates (0.9mm medial-lateral, 3.0mm posterior,1.8mm ventral) 
from lambda. Animals were sacrificed by transcardiac perfusion with 4% PFA + 0.25% 
glutaraldehyde at 13 week post transplantation, and 50um sagittal brain sections were used for 
immunohistochemistry. Quantification of stained MBP and human specific marker STEM121 
was done by calculating % STEM121+ cells that coloalize with MBP staining.  
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OPC differentiation on human slice culture 
Fetal cortical tissue (gestational weeks 20 to 23) was collected from elective pregnancy 
termination specimens at San Francisco General Hospital with previous patient consent. 
Research protocols were approved by the Committee on Human Research (Institutional Review 
Board) at University of California, San Francisco. Human slice culture was prepared as 
described5. Cultured iPSC-derived spheres at day 40-45 were dissociated with accutase, 
resuspended in PDGF medium, and labeled with GFP lenti virus overnight. Cells were washed 
twice to remove viral particles, resuspended in approximately 6ul DMEM/F12, and plated onto 
human slice culture prepared a day before. Three weeks post plating, a subset of the grafted 
cells gave rise to NeuN+ neurons, with a similar efficiency between mutant and corrected cells 
(Extended Data Fig. 6b). Another fraction of the EGFP+ cells differentiated to MBP expressing 
mature oligodendrocytes. Slice culture was fixed with 4% PFA for 15min, cryoprotected, and 
sectioned at 14um for immunohistochemistry. To quantitatively assess the degree of 
oligodendrocyte maturation, we classified the EGFP+/MBP+ cells into three categories based on 
morphological complexity (differentiated, immature, abnormal). 
 
Jimpy in vitro OPC differentiation assay 
Cortical OPCs were immunopurified from postnatal day 5-8 Jimpy or wildtype littermate mice as 
described6. After 3 days in culture with proliferation factor PDGF-AA, OPCs were directed to 
differentiate by removal of PDGF-AA and addition of a differentiation factor T3. Cells were fixed 
24hrs after initiation of differentiation for histological analysis. Deferoxamine was added to 
media throughout the four-day culture at 10uM concentration. 
 
Jimpy in vivo iron chelation treatment 
Jimpy mice were subcutaneously injected with 30mg/kg deferiprone (Sigma 379409) in sterile 
PBS, during P7 to P14 and P21 to P28 for survival study, and P7 to P14 for ER stress/UPR 
study. Care was taken to minimize disturbance of the mice during injection to avoid seizures. 
For histological assays requiring electron microscopy assay, brains were collected after cardiac 
perfusion with 4% PFA containing 0.25% glutaldehyde at P28 and sectioned with a vibratome. 
Quantification of GFAP and Iba1 was done by calculating fluorescent intensity in stained 
sections. 
 
Fluorescent in situ hybridization 
Three-color smFISH was performed on corpus collosum containing fixed frozen sections from 
Jimpy mice using Advanced Cell Diagnostics RNAscope® Fluorescent Multiplex Reagent Kit 
and probes. Briefly, cryosections (14µm thick) were mounted on glass slides and washed in 
RNase free PBS for 5 mins and baked at 60°C for 30 mins and were further fixed in 4% 
neutral buffered paraformaldehyde for 15 min at 4°C. Next, sections were dehydrated in 
50%, 70% and 100% ethanol for 5 mins at room temperature and air dried. Target retrieval 
was then performed with RNAscope reagents for 3 mins at 95 °C and sections were further 
washed with distilled water followed by washes in 100% ethanol 2-3 times. After drying, 
sections were permeabilized with Protease IV reagent for 15 mins at 40°C, washed and 
maintained in RNase free water until hybridization step. Probes (Mm-Atf4 (405101), Mm-
Pdgfra-C2 (480661-C2), Mm-Ddit3-C3 (317661-C3); C2 and C3 probes were diluted at 1:50 
ratio in channel 1 probe) were mixed and preheated to 40°C for 5 mins and then added to the 
sections for 2hr at 40°C. After probe hybridization, sections were washed two times 2 mins 
each and further incubated in AMP 1-FL for 30 min at 40°C, washed two times, incubated in 
RNAscope AMP 2-FL for 15 min at 40°C, washed two times, incubated in RNAscope AMP 3-FL 
for 30 min at 40°C, washed two times and incubated in AMP 4-FL-Alt B solution for 15 mins at 
40°C, washed two times and counterstained with RNAscope DAPI for 30 seconds. All wash 
steps were performed with RNAscope 1x wash buffer.  Where indicated, after the RNAscope 
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assay, the slides were blocked in 5% Horse serum/0.05% TX-100 in PBS, followed by 1 hr of 
primary antibody incubation at RT, followed by three washes in PBS and secondary antibody 
incubation for 1hr at RT and mounted with prolong gold antifade. Quantification of RNA spots 
was performed on images acquired at 63x on Lecia SP5 upright AOBS confocal microscope.  
  
Antibodies 
Following primary antibodies were used. 
Olig2 (courtesy of Charles Stiles) 
NKX2.2(Developmental Studies Hybridoma Bank 74.5A5) 
SOX1 (R&D AF3369) 
PAX6 (Developmental Studies Hybridoma Bank Pax6) 
O4 (Mouse hybridoma) 
PLP1 (Abcam) 
MBP (AbD Serotec MCA409S) 
Cleaved Caspase-3 (Cell Signaling 9664S) 
KDEL (Abcam ab50601) 
GFP (Aveslab GFP-1020) 
Human cytoplasmic (Clontech STEM121) 
NeuN (EMD Millipore MAB377) 
PDGFRa (BD Bioscience 556001) 
Transferrin (Abcam ab137744) 
Ferritin (Novus Biologicals NB600-920) 
IRP1 (Cell Signaling 20272) 
IRP2 (Cell Signaling 37135S) 
Transferrin receptor (BD Bioscience 561939) 
Ferroportin (Novus Biologicals NBP1-21502) 
beta Actin (Sigma A5441) 
GFAP (Fisher 13-0300) 
Iba1 (Wako 019-19741) 
EIf2D (Cell Signaling 9722) 
Phospho-EIf2D (Fisher MA5-15133) 
ATF4 (Aviva Systems Biology ARP37017) 
CHOP (Fisher MA1-250) 
 
Secondary antibodies of appropriate species were purchased from Jaxon ImmunoResearch and 
Life Technologies.  
 
qPCR primers  
For quantitative PCR, total RNA was isolated at described time points with Trizol reagent (Life 
Technologies) or RNAeasy Mini Kit (Qiagen) following manufacturer’s protocols. Contaminating 
DNA was removed with TURBO DNA-free kit (Life Technologies). cDNA was obtained with 
High-capacity cDNA reverse transcription kit (Life Technologies). SYBR green-based qPCR was 
conducted in LightCycler 480 with manufacturer’s reagents (Roche) with the following primer 
sets: 
 
PAX6 FW: TTTGCCCGAGAAAGACTAGC RV: CATTTGGCCCTTCGATTAGA  
OLIG2 FW: TGCGCAAGCTTTCCAAGAT RV: CAGCGAGTTGGTGAGCATGA 
SOX1 FW: GGAATGGGAGGACAGGATTT  RV: AACAGCCGGAG CAGAAGATA  
NKX2.2 FW: GACAACTGGTGGCAGATTTCGCTT RV: AGCCACAAAGAAAGGAGTTGGACC 
Spliced XBP1 FW: CTGAGTCCGCAGCAGGTGCAG RV: GGTCCAAGTTGTCCAGAATGCCC 
BIP FW: CCGCTGAGGCTTATTTGGGA RV: TCTTTGGTTGCTTGGCGTTG 
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ATF3 FW: CTCGGGGTGTCCATCACAAA RV: TTGTTTCGGCACTTTGCAGC 
HMOX1 FW: GAGGAACTTTCAGAAGGGCCA RV: CCTTGTTGCGCTCAATCTCC 
SOD3 RW: GTGCAGCTCTCTTTTCAGGAG RV: GAGCAGGCAGGAACACAGTAG 
ATOX1 FW: CGGGTCCTCAATAAGCTTGGA RV: AGGGTTGCAAGCAGAGTGTC 
SCARA3 FW: CCGAAGACATCTCCTTGACCC RV: GCAGTTGTTCAGGGCTTTCG 
TXNIP RW: ACCTGCGCTATGAAGACACG RV: AAGCTCAAAGCCGAACTTGT 
SOD2 FW: GTTGGGGTTGGCTTGGTTTC RV: CCCCAGCAGTGGAATAAGGC 
TXN FW: GGACGCTGCAGGTGATAAAC RV: CGTTGGAATACTTTTCAGAGAGGG 
TXNRD2 FW: ATGATCTCCTGGTGGTCGGC RV: TGGGGAGAAGGTTCCACGTA 
TF FW: GATGCTTACCTGGCTCCCAATAAC RV: CTTCTTCACCACAGCAACAGCAT 
IRP1 FW: CTTGGGTCAGGTTCGCCG RV: TCCAGGATGGTGGAAACTGC 
IRP2 FW: GGCAGAAATCGAGAGAGGCT RV: TGAGCCATTCCAGTTCCAGG 
TFRC FW: TTGGACATGCTCATCTGGGG RV: CCTGATGACCGAGATGGTGG 
APP FW: GATCCCAAGAAAGCCGCTCA RV: CACTGCAGGCACGTTGTAGA 
CP FW: AGCTGGAACAGAGGATTCTGC RV: GACAAACAATCAGGGGGCCA 
P53 FW: ACCTATGGAAACTACTTCCTGAAAA RV: CAATATCGTCCGGGGACAGC 
SAT1 FW: CAGTGACATACTGCGGCTGAT RV: AGGGGTGCTCTCCAAAACC 
PLP1 FW: TATCTCATCAATGTGATCCATGCCT RV: TCCTAGCCATTTTCCCAAACAAT 
DM20 FW: TATCTCATCAATGTGATCCATGCCT RV: CCACAAACGTTGCGCTCA 
 
Electron Microscopy 
Animals were cardiacly perfused with 4% PFA containing 0.25% glutaldehyde. Alternative 
vibratome sections were kept for immunohistochemistry and EM, which were post-fixed in 4% 
glutaraldehyde for several days. Regions of interest determined by immunohistochemistry were 
micro-dissected, fixed in 2% osmium tetroxide and embedded in resin. Ultrathin sections were 
placed onto copper grids, stained with uranyl acetate and lead, and examined with a Hitachi H-
600 or TEM 1400 Transmission Electron Microscopes. Use of TEM 1400 was supported by NIH 
grant SIG number 1S10RR02678001. 
 
Flow Cytometry 
The bulk culture was detached using Accutase, dissociated, rinsed, and resuspended in PBS 
containing1% BSA. Cells were incubated with O4-APC (Miltenyi Biotec Inc 130-099-211) and 
TFRC-GFP (BD Biosciences 561939) for 10min at room temperature. Following a wash with 
PBS, cells were suspended in PBS containing 5mM EDTA and analyzed with FACSAria II Cell 
Sorter (BD Biosciences) and FACSDiva software (BD Biosciences). Dead cells were excluded 
by Dapi staining.  
 
Morphological complexity assessment 
Cultures at described days were live-stained with O4 antibody for 30min, followed by Cy3-
conjugated secondary antibody for 30min. After fixation, images were taken at 40X 
magnification in Leica microscope equipped with CCD camera. Individual cell morphology was 
reconstructed by tracing the O4 stained branches assisted by a Fiji plugin software Simple 
Neurite Tracer7. Traced images were analyzed with Sholl analysis software (Fiji)8. Ramification 
index, which integrates the number of branches from soma and number of intersections, as well 
as the total length of traced line were presented in results.  
 
Reactive oxygen species assessment  
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General ROS assessment: After live O4 staining to identify OPCs, the CellROX® ROS sensor 
(Life Technologies) was used at 1:500 dilution of the ROX reagent following manufacturer’s 
protocol, with a following modification: incubation with ROX reagent was increased to 60min.  
Lipid ROS assessment: Click-iT® Lipid Peroxidation Detection with Linoleamide Alkyne (LAA) 
(Life Technologies) was used following manufacturer’s protocol with the following modifications: 
LAA stock solution was added to the culture at 10uM concentration from day 49 to 55 every 
other day. On day 55, cultures were live-stained with O4 first, then manufacturer’s LAA 
detection protocol was followed. Quantification of LAA+ cells was conducted under Leica 
microscope equipped with CCD camera within 2 days of detection.  
 
Western blot analysis 
Isolated 50,000 O4+ oligodendrocytes were pelleted and snap frozen until analysis. Cell pellet 
was homogenized in lysis buffer, separated by electrophoresis following manufacturer's protocol 
(Bolt Mini gel, Thermo Fisher), transferred, and incubated with primary antibodies overnight. 
Proteins were visualized using Licor Western blot detection system. 
 
Isolation of human primary OPCs  
Fetal brain tissues described in the human slice culture section was dissociated with papain for 
10min. Single cell suspension was passed onto series of culture dishes coated with BSL 
(Bandeiraea Simplicifolia Lectin I, Vector Laboratories L1100) to remove microglia and 
endothelial cells, IgM secondary antibody (Jackson immunolab 115-005-020) to avoid non-
specific binding, and O4 (Mouse hybridoma), to isolate O4+ OPCs. At the end of O4 binding, 
adherent cells were washed, and detached with Trypsin, and collected by centrifugation. Cells 
were directly homogenized in Trizol for RNA collection.  
 
Statistics 
Each in vitro experiment was repeated at least three times. 2-to-3 biological replicates were 
included in each experiment.  
In vivo experiments were repeated using at least randomly assigned 5 mice per treatment 
group, considering unexpected dropout often due to strain vulnerability to seizures. For 
statistical analysis, two sided one way ANOVA and t-test with normal distribution, log-rank 
survival test, or one way Chi-square tests were used as appropriate. * indicates p-value<0.05, ** 
p-value<0.01, *** p-value<0.001, n.s. = not significant. Data are presented as mean ± SEM.  
 
Data Availability 
The data that support the findings of this study are available from the corresponding author 
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